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Michel M. P. J. Reijnen, MD, PhD,b Arnhem and Groningen, The Netherlands
Background: Focal infrarenal aortic occlusive disease requiring treatment is an uncommon condition. Short lesions may
be treated endovascularly, while long lesions are traditionally treated by surgery. Advances in endovascular devices,
including development of covered stents, may expand endovascular options. This study evaluates the feasibility, safety,
andmidterm results of primary polytetrafluoroethylene (PTFE)-covered stenting of isolated atherosclerotic lesions of the
infrarenal aorta.
Material andMethods:BetweenNovember 2008 andMarch 2011, 12 patients, aged 59 (42 to 78) years, were treated with
a balloon-expandable PTFE-covered stent for a focal infrarenal aortic stenosis (n 11) or occlusion (n 1). Indications
included disabling claudication (n  9), rest pain (n  1), or minor tissue loss (n  2) Follow-up consisted of clinical
examination, ankle-brachial indexes, plain abdominal radiography and duplex ultrasonography.
Results: Eleven procedures were performed percutaneously and one in combination with an endarterectomy of the right
common femoral artery. Technical success was 100%, and clinical improvement was achieved in all but one patient, who
needed additional femoropopliteal bypass surgery. The median follow-up was 18 months (range 2-30 months). During
follow-up, all patients remained asymptomatic and ankle-brachial indexes had normalized. Duplex ultrasonography
showed no re-stenosis, and there were no stent fractures on abdominal radiographs.
Conclusions: The primary use of PTFE-covered stents is a feasible, effective, and safe treatment for focal atherosclerotic
lesions in the infrarenal aorta. Comparative studies with traditional treatment modalities, however, are indicated before
considering the use of covered stents as standard treatment. (J Vasc Surg 2012;55:674-8.)
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lFocal infrarenal aortic occlusive disease is an infrequent
manifestation of atherosclerosis and is predominantly seen in
relatively young female smokers with elevated lipid profiles.1
TheTransAtlantic Inter-SocietyConsensus (TASC-II) guide-
lines have recommended endovascular treatment for lesions
up to 3 cm length, while for aortoiliac occlusions, surgery is
recommended.2 The 5-year patency rate of surgical recon-
struction is reported to be 91% for patients with claudication
and 87% for patients with critical ischemia, respectively.3,4
Surgical aortic reconstruction, however, is related to 8.3% to
12.2% complication and 3.3 to 4.4% mortality rate.5 More-
over, a laparotomy may induce late complications, including
incisional hernia and small bowel obstruction, supporting the
search for minimally invasive alternatives.
The safety and feasibility of percutaneous transluminal
angioplasty and, more recently, bare metal stenting, has
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674een established since the 1980s, but mainly for relatively
hort lesions.6-9 Recent studies have described a 1-year
rimary patency rate of primary aortic stenting of 85% to
8%.10,11 Literature focusing on eccentric calcified and
lcerative aortic lesions is lacking. Endovascular treatment
f focal aortic lesions has been related to a major complica-
ion rate up to 16%11 and may include vessel wall rupture
nd distal embolization. Vessel wall rupture is more likely
o occur with balloon expandable stents as opposed to
elf-expanding stents. Various reports describe the endo-
ascular treatment of aortoiliac occlusions with acceptable
idterm results. Klonaris et al12 described a series of 12
atients with infrarenal aortic occlusive disease who were
reated with primary stenting. After a mean follow-up of
8.3 months, the primary patency was 92%. In another
eries, Ozkan et al13 described a small series of five patients
ho were treated endovascularly for a total aortoiliac oc-
lusion. Technical success was achieved in four and, after a
edian follow-up of 18 months, the aortic and iliac stents
emained patent.
Growing evidence is supporting the use of covered
tents in extensive iliac occlusive disease.14,15 By covering
he entire diseased segment, they may reduce the incidence
f in-stent re-stenosis, thereby improving patency. More-
ver, they might reduce the risk of rupture and emboliza-
ion, especially in heavily calcified eccentric or ulcerative
esions. Schwindt et al16 have recently described the suc-
essful use of self-expandable covered stents in two patients
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Volume 55, Number 3 Bruijnen et al 675with a friable thrombus, in order to prevent embolization.
The primary use of balloon expandable covered stents for
isolated aortic occlusive disease has not been described, to
date.
The aim of the present study was to assess the safety,
feasibility and outcome of polytetrafluoroethylene (PTFE)-
covered balloon-expandable stents in the treatment of iso-
lated infrarenal aortic lesions.
METHODS
Study population. Case files of all patients that were
treated in the Rijnstate Hospital for isolated infrarenal
aortic occlusive disease from November 2008 and March
2011 were studied. Demographics, medical history, and
ankle-brachial indexes (ABI) were noted. Preprocedural
imaging studies (Fig 1), procedural findings, and clinical
status were studied. Patients with involvement of the aortic
bifurcation and iliac arteries requiring kissing stents were
excluded, since the aim of the study focused on isolated
infrarenal aortic lesions. Patients with isolated aortic lesions
were preferably treated endovascularly in our center. Pa-
tients with extensive aortic lesions extending into one or
both common iliac arteries were treated surgically during
the study period.
On duplex scan, a stenosis with a peak systolic velocity
(PSV) ratio of2.5 was considered to be significant. Tech-
nical success was defined as a successful vascular access,
completion of the endovascular procedure, as well as im-
mediatemorphologic success, with30% residual diameter
reduction and exact deployment of the stent graft on
postprocedural angiography. Clinical success was defined as
either the absence of symptoms or improvement by at least
one category according to the Rutherford classification.
Primary patency was defined as a patent stent graft without
Fig 1. Three-dimensional reconstruction (A) and tran
scan of a 48-year-old male patient, suffering from Ruther
0.3, showing an isolated infrarenal subtotal stenosis.any reintervention. Primary assisted patency was defined as dpatent stent graft after endovascular reintervention but
ithout occlusion at any time. Secondary patency was
efined as a patent stent graft after occlusion, with patency
nding with an untreated or surgically treated occlusion.
Treatment protocol. Patients were preferably treated
sing local anesthesia in the interventional angio suite.
hen patients required an additional surgical intervention,
he procedure was performed in the operating theater. A
etrograde percutaneous access to the common femoral
rtery was obtained using the Seldinger technique and an
F introducer sheath was placed. Patient received 5000 IU
eparin. The lesions were crossed using a 0.035 Terumo
ire (TerumoMedical Corporation, Elkton, Md) and a 5F
ush catheter (VCF; Cook Medical Inc, Bloomington,
nd). Subsequently, a diagnostic digital subtraction angio-
ram (DSA) was performed (Fig 2, A). After removing the
atheter, the delivery system was positioned and a balloon-
xpandable PTFE-covered stent (Advanta V12 LD; Atrium
edical, Hudson, NH) was deployed. If indicated, the
tent grafts were postdilated using a 14-mm percutaneous
ransluminal angioplasty balloon (Wanda; Boston Scien-
ific, Natick, Mass). The delivery system was then replaced
y the flush catheter and angiography was performed to
nsure proper location and deployment (Fig 2, B). Post-
rocedural, the distal runoff was assessed. Hemostasis was
chieved using an 8F femoral closure device (Angioseal, St.
ude Medical, St. Paul, Minn). Patients were treated with
cetylsalicylic acid 80 mg daily, unless oral anticoagulation
as indicated for other pathology, and statin medication.
ollow-up consisted of clinical assessment, duplex ultra-
onography, and ankle-brachial indexes at 3, 6, 12, and 24
onths. Plain abdominal X-ray was performed at 12 and 24
onths.
Statistical analysis. Two-tailed statistical analysis of
l section (B) of a preoperative computed tomography
category 5 with a bilateral ankle-brachial index (ABI) ofsversa
fordifferences between groups was performed using the non-
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March 2012676 Bruijnen et alparametric Mann-Whitney U test using the StatView soft-
ware version 5.0.1 (SAS Institute Inc, Cary, NC). A P value
.05 was considered statistically significant.
RESULTS
Demographic data. During the study period, a total
of 12 patients were treated with PTFE-covered stents for
focal infrarenal aortic occlusive disease. The median age
was 59 (range 42-78) years and the male-to-female ratio
was 1:3. Patients presented with Rutherford category 2
(n  1), 3 (n  8), 4 (n  1), and 5 (n  2). All patients
were smokers. Nine patients had dyslipidemia, two suf-
fered from diabetes mellitus, seven patients had hyper-
tension, and two patients had a cardiac history. The
median preprocedural ABI was 0.75 (range 0.31-0.93)
on the right side and 0.74 (range 0.28-0.90) on the left
side. One patient had previously been treated with an
aortobifurcation prosthesis and presented with a stenosis
of the proximal anastomosis.
Preprocedural imaging. All patients were evaluated
using duplex ultrasound scanning and all but one under-
went computed tomography (CT) scanning. In the remain-
ing patient, the intervention was scheduled on duplex only.
A focal aortic stenosis was found in 11 patients and one
patient had a total occlusion. The median grade of stenoses
was 75% (range 67%-91%) Themedian lesion length was 35
mm (range 10-58 mm). Ten of 12 (83%) stenosis were
eccentric and two (17%) were concentric. In nine out of 12
(75%) patients, the lesion was heavily calcified and six
patients (50%) had an ulcerative plaque.
Procedure. Eleven procedures were performed percu-
taneously using local anesthesia only. One patient under-
went a concomitant endarterectomy of the right common
femoral artery under general anesthesia. Technical success
was achieved in all patients, and all stent grafts were placed
without predilatation. The median duration of the proce-
Fig 2. A and B, Procedural angiogram confirming
Postprocedural angiogram showing a good deployment
Medical, Hudson, NH) without residual stenosis. Patien
(ABI) had normalized.dure was 45 minutes (range 20-90 minutes), with a median suoroscopy time of 4.26 minutes (range 3.20-13.56 min-
tes), and a median of 75 mL (range 50-190 mL) contrast
edia was used. The used diameters of stent grafts were 12
m (n  11) and 10 mm (n  1) with a length of 4 cm
n  9) and 6 cm (n  3). Lesion characteristics of each
atient have been described in the Table.
There were no vessel wall ruptures, dissections, or signs
f distal embolization. One patient developed pain and
mpaired coordination of her right leg during the proce-
ure, most likely caused by a femoral nerve neuropathy.
epeated magnetic resonance scanning of the myelum
howed no signs of ischemia or infarction. The symptoms
esolved spontaneously within months after treatment.
ther complications included two conservatively treated
ccess-site hematomas.Most patients were discharged from
he hospital on the first postprocedural day (range 0-6
ays).
Follow-up. Postoperatively, all but one patient sho-
ed clinical improvement. This patient was known to have
n occluded femoropopliteal artery and underwent addi-
ional successful femoropopliteal bypass surgery. It was
ecided to perform the central reconstruction first, to im-
rove inflow. After the femoropopliteal bypass surgery, the
atient improved to Rutherford 0. The median Rutherford
lassification improved from 3 (range 2-5) to 0 (range 0-2).
fter a median follow up of 18 months (range 2-30), no
atient had clinical signs of re-stenosis. Postoperatively, the
edian ankle-brachial indexes had increased to 1.09 (range
.79-1.21, P  .01) on the right side and 1.02 (range
.76-1.32, P  .01) at the left side, respectively, and did
ot decrease during follow-up. Duplex ultrasonography at
(n 11), 6 (n 10), 12 (n 9), and 24 (n 4) months
howed no re-stenosis or edge stenosis. There were no
econdary interventions during follow-up. Abdominal ra-
iographs at 12 and 24months follow-up demonstrated no
ubtotal stenosis in the 48-year-old male patient. C,
cm long 12 mm Advanta V12 LD stent graft (Atrium
improved to Rutherford 0 and the ankle-brachial indexthe s
of a 6
t hadtent migration or stent fracture.
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Data from the present study have shown that the use of
PTFE-covered stents for isolated atherosclerotic lesions in
the infrarenal aorta is safe, feasible, and associated with an
excellent outcome. During follow-up, all stents remained
patent, which indicates that covered stents may be a valid
alternative for surgery.
The high patency rate observed in our study is in
accordance with the recent studies that showed that cov-
ered stents are associated with a significantly increased
patency rate in complex iliac occlusive disease. Unfortu-
nately, we were able to include only 12 patients, rendering
the series too small to make any reliable comparison with
previous publications on bare metal stents or a historic
control group due to underpower. Sabri et al14 have com-
pared 26 patients who were treated with kissing covered
stents with a historical control group and showed that the
use of covered stents increased the primary patency from
62% to 92%. Additionally, the multicenter randomized
Covered Versus Balloon-Expandable Stent (COBEST)
trial, which compared the use of covered stents to bare
metal stents in iliac occlusive disease, has shown that cov-
ered stents significantly improve patency rates in TASC-II
C and D lesions.15 This may be related to the fact that
covering of the diseased segment will reduce the risk on
in-stent re-stenosis, thereby increasing patency rates. It
must be noted, however, that isolated aortic disease is likely
to be different from bifurcation and isolated iliac disease
from a hemodynamic standpoint. Our results on focal
aortic lesions are limited by the small sample size and study
design. Comparative studies are required to assess the exact
role of covered stents in the treatment algorithm of isolated
aortic occlusive disease. The relative rareness of this pathol-
ogy, however, might complicate the design of comparative
studies.
In the present study, 83% of patients had a heavily
calcified eccentric lesion. Although rarely described, eccen-
Table. Anatomical characteristics of the treated lesions
Patient
Grade of
stenosis (%)
Lesion length
(mm)
Diameter aorta
(mm)
Proximal Dista
1 67% 15 16 15
2 100% 58 14 13
3 65% 15 12 11
4 82% 51 12 12
5 81% 40 18 14
6 61% 39 16 14
7 70% 12 15 13
8 75% 36 15 14
9 74% 11 15 14
10 70% 29 15 14
11 87% 25 16 16
12 91% 26 14 14
IMA, Inferior mesenteric artery.tric heavily calcified lesions are likely to carry increased risk rf vessel wall rupture during dilation. It, therefore, seems
easonable to assume that endovascular treatment in these
atients is often refused. In two recently published series of
are metal stenting, the incidence of vessel wall rupture was
pproximately 2%.11,16 A potential advantage of the use of
are stents could be that one may oversize the stent,
alloon the area with a smaller balloon enough to crack it,
nd allow the stent to expand over time to avoid rupture. In
he present series, we did not observe any vessel wall
upture. Theoretically, the PTFE would have immediately
overed the rupture, when occurred. A rupture of the
TFE covering material, due to dilatation of a heavily
alcified lesion, has never been described to our knowledge.
Covered stents might also reduce the incidence of
mbolization, by covering the vulnerable ulcerative plaque,
s was present in half of our patients. This strategy has
ecently been proposed in another retrospective series,
sing self-expandable stents in two patients.16 In our pa-
ients, there were no clinical signs of emboli, which is in
ccordance with previous case series of patients treated with
overed stents for iliac occlusive disease.14,17 In the
OBEST trial, the incidence of thromboemboli, using
ith either covered or bare metal stents, was 1.2%.15
In our study group, seven patients suffered from a
ASC-II type B lesion. These include stenosis 3 cm in
ength, and an endovascular procedure is recommended
nless an open revascularization procedure is required for
ther lesions in the same anatomic area. To our surprise, we
ere unable to adequately categorize the remaining five
esions properly into TASC-II categories.2 One patient
uffered from an isolated aortic occlusion and the remain-
ng four patients had a stenosis longer that 3 cm. Isolated
nfrarenal aortic lesions are not described in types A and C,
hile a type D lesion is defined as an infrarenal aortoiliac
cclusion, which was not the case in our patients. The
bservation that five out of 12 patients may not be catego-
IMA
Origin
Distance of the lesion to
Mural
thrombus
Renal arteries
(mm)
Aortic bifurcation
(mm)
Occluded 27 42 No
Occluded 7 18 Yes
Patent 8 49 No
Patent 35 29 No
Occluded 45 24 No
Occluded 25 15 Yes
Patent 76 8 No
Patent 8 44 Yes
Patent 71 44 No
Patent 89 14 Yes
Patent 42 18 No
Patent 58 23 Nolized indicates that the current version of the TASC-II
11
1
1
1
1
1
1
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The use of covered stents may increase procedural
costs. A proper cost-benefit analysis has not been published
to date. An increased patency rate, as is shown in extensive
iliac disease, combined with a possible decrease in compli-
cations might render the procedure cost effective. Without
randomized studies, however, it might be more cost effec-
tive to reserve covered stenting for cases in which rupture is
suspected. Studies focusing on the use of various tech-
niques in relation to quality adjusted life years are therefore
required.
In conclusion, we have shown that the use of covered
stents for isolated aortic occlusive disease is safe, and related
to low morbidity and excellent patency rates. Comparative
studies with traditional treatment modalities are indicated
to assess the role of covered stents in the treatment strategy
of these lesions.
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The authors report a series of patients with focal infrarenal aortoiliac
occlusive disease that was treated with polytetrafluoroethylene-
covered stenting. Although this is a small series, it provides
valuable information on a problem encountered frequently
enough in clinical practice and shows that primary use of
polytetrafluoroethylene-covered stents is a feasible, effective,
and safe treatment for focal atherosclerotic lesions in the infra-
renal aorta. With a median follow-up of 18 months, there were
no instances of restenosis and no need for any secondary inter-
ventions.
It should be particularly noted that all patients were treated
with a balloon-expandable stent, with no reported adverse
events of aortic rupture. In addition, 67% of the patients had a
patent inferior mesenteric artery, and 33% had aortic mural
thrombus, with no reported cases of bowel ischemia or embo-The reader is correct to be somewhat skeptical of drawing broad
onclusions from a small series that lacks a control group undergoing
ngioplasty or bare-metal stenting, but the results will expand our
nowledge, inform future study, and impact the clinical care of
atients with focal infrarenal aortoiliac occlusive disease. The results of
his series, albeit limited, also seem to dismiss some of the concerns
ssociated with the endovascular treatment of aortic occlusive disease
uch as a high recurrence rate, risk of iatrogenic rupture, risk of colonic
schemia, and the presence of heavily calcified lesions that would be
esistant to angioplasty and stenting.
Stenting for focal infrarenal aortoiliac occlusive disease appears
o be an attractive alternative treatment option for such patients.
owever, longer follow-up, and as the authors rightfully conclude,
dditional comparative studies with traditional treatment modali-
ies, are needed before considering the use of covered stents as the
rst-line standard treatment.
